* Simeprevir (Olysio) is a new protease inhibitor approved for the treatment of adults with hepatitis C viral infection. Simeprevir should be used as part of a combination therapy treatment plan.
* Genotype 1a hepatitis C virus with the NS3 Q80K polymorphism will not respond well to simeprevir therapy.
* Common adverse effects are rash (including photosensitivity), pruritis, and nausea.
Diane S. Aschenbrenner recently retired as course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: email@example.com.